Orphan Drug Designation Granted to Gene Therapy Program for Infantile Batten – Rare Disease Report
Rare Disease Report |
Orphan Drug Designation Granted to Gene Therapy Program for Infantile Batten
Rare Disease Report This morning, Abeona Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to its ABO-202 program (AAV-CLN1) for the treatment of infantile Batten disease. Preclinical data of the adeno … Abeona Therapeutics Receives FDA Orphan Drug Designation for … |
